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ABSTRACT: Neuromuscular diseases result in muscle weakness,
disability, and, in many instances, death. Preclinical models form
the bedrock of research into these disorders, and the development
of in vivo and potentially translational biomarkers for the accurate
identification of disease is crucial. Spontaneous Raman spectros-
copy can provide a rapid, label-free, and highly specific molecular
fingerprint of tissue, making it an attractive potential biomarker. In
this study, we have developed and tested an in vivo intramuscular
fiber optic Raman technique in two mouse models of devastating
human neuromuscular diseases, amyotrophic lateral sclerosis, and
Duchenne muscular dystrophy (SOD1G93A and mdx, respectively).
The method identified diseased and healthy muscle with high
classification accuracies (area under the receiver operating characteristic curves (AUROC): 0.76−0.92). In addition, changes in
diseased muscle over time were also identified (AUROCs 0.89−0.97). Key spectral changes related to proteins and the loss of α-
helix protein structure. Importantly, in vivo recording did not cause functional motor impairment and only a limited, resolving tissue
injury was seen on high-resolution magnetic resonance imaging. Lastly, we demonstrate that ex vivo muscle from human patients
with these conditions produced similar spectra to those observed in mice. We conclude that spontaneous Raman spectroscopy of
muscle shows promise as a translational research tool.
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■ INTRODUCTION
The development of biomarkers to identify and track
pathology in disorders of nerves and muscles (termed
collectively, neuromuscular disorders) is central to efforts
aimed at improving the lives of patients with these disorders.
For example, better determination of disease state would allow
clinicians to intervene earlier in disease course, while also
improving clinical trial design. Neuromuscular diseases cause
considerable mortality and morbidity with annual per patient
costs typically in excess of $50 000;1 as a result, these
conditions are intensively researched in both preclinical and
clinical settings. Two examples are amyotrophic lateral
sclerosis (ALS) and Duchenne muscular dystrophy (DMD).
ALS is an incurable neurodegenerative disorder charac-
terized by dysfunction and death of motor neurones in the
brain and spinal cord, resulting in muscle weakness and death.2
Interestingly, there is evidence that muscle pathology can
occur independently of neurone loss and starts early in
disease,3,4 making muscle an attractive target for biomarker
development. Preclinical models of the disease, usually mouse
models, are crucial for understanding the pathobiology of the
condition. Of those available, mice overexpressing the human
mutant superoxide dismutase-1 (SOD1) gene are the best
studied.5 However, it is now recognized that a lack of sensitive
biomarkers of disease has hampered ALS preclinical studies.6
In vivo biomarkers presently in use include time-consuming
gait analysis systems and phenotype scores,7 expensive imaging
tools, such as magnetic resonance imaging (MRI),8 and
challenging electrophysiological measures.9
While ALS is typically encountered in the second half of life,
DMD is the most common, fatal muscle wasting disease of
childhood with a birth prevalence of up to 19.5 per 100 000
live births.10 It is an X-chromosome linked recessive disease
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caused by mutations (most commonly deletions) in the
dystrophin gene. The ensuing absence/reduction in the
cytoskeletal protein dystrophin results in muscle damage
caused by repeated contractions. The mdx mouse is the most
studied model of DMD.11 The mdx phenotype is relatively
mild, and as a result, there are few in vivo methods for studying
disease onset and progression. Techniques such as wire
hanging and grip strength struggle to identify the mild
symptoms and are confounded by animal weight and
behavior;12 furthermore, some papers report using groups of
up to 100 mice.13 As a result, muscle force studies and
histological studies are done after sacrificing the animals in
order to definitively study muscle pathology. Sensitive in vivo
detection of the disease state therefore remains an area of
unmet need.
Spontaneous Raman spectroscopy uses laser light of a single
frequency to stimulate the vibrational modes of molecules
within a sample. When assessing tissue samples, the resulting
Raman spectrum provides a “biochemical fingerprint”.14
Biomedical applications of the technology are achieving
sensitive, real-time tissue analysis across different tissues in
cancer.15−19 Pertinent to the present study, a recent report
used stimulated Raman scattering microscopy in vivo to study
nerve pathology in several mouse models of ALS.20 In
addition, spontaneous Raman has been used to study the
spinal cord in the SOD1G93A model21 and to examine fly
models of human muscle diseases (myopathies).22 While these
studies require either technically challenging in vivo methods
or rely on ex vivo analysis, they demonstrate the potential of
the technique for the study of neuromuscular disorders.
Indeed, there are few in vivo techniques capable of providing
the molecular information obtained through Raman spectros-
copy.
Our aim in this study was to develop and test a methodology
for identifying muscle pathology in vivo in different mouse
models of fatal neuromuscular diseases. Detecting the weak
Raman signal within living tissue poses technical challenges
relating to miniaturization, targeting the light to the organ of
interest, photoluminescence, and spectral artifacts from probe
components (e.g., silica). We have overcome these challenges
and developed a simple, minimally invasive fiber-optic-based
method for the label-free study of living muscle in preclinical
models of devastating human diseases. Together with data
from ex vivo human patient samples, the results highlight the
growing potential of Raman spectroscopy as a translational
biomedical research tool.
Figure 1. Intramuscular, in vivo, fiber optic Raman spectroscopy assessment. (a) A flowchart of the experiments. (b) A schematic of the fiber optic
Raman system. (c) A mouse undergoing the procedure; the laser light can be appreciated within the hindleg as the camera used does not filter out
the light. (d) Raman spectra obtained from muscle, blood, and bone. See Supporting Information Table 1 for tentative peak assignments and
references.
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■ RESULTS AND DISCUSSION
Using the SOD1G93A model of ALS and mdx model of DMD,
we were able to record spectra from living muscles, which were
clearly different from those of neighboring tissues such as
blood and bone (Figure 1, Supporting Information Figure 1).
Tentative peak assignments for all tissues can be found in
Supporting Information Table 1. Mean muscle spectra, both
with (Figures 1 and 2) and without (Supporting Information
Figure 2) baseline subtraction, comprised peaks relating to the
key constituents of muscle such as myosin, tropomyosin, and
actin (Supporting Information Table 2). As expected, these
prominent peaks were common to muscle from both murine
models. Muscle histology demonstrated both the underlying
similarity of the muscle and the pathological features of each
model (Figure 2).
In order to test the ability of the in vivo intramuscular
method to detect muscle disease and visualize more subtle
differences in the spectra, we employed a range of multivariate
techniques. Results for two-group PCA-LDA are shown in the
main text (Table 1); data from PCA-QDA and PLS-DA are
presented in Supporting Information Tables 3−5.
In the SOD1G93A model, the 30 day time-point is prior to
disease onset; by 90 days, the mice have established
disease.7,23,24 This was apparent in the classification perform-
ance. At 30 days, discrimination between transgenic (Tg) and
non-transgenic (NTg) mice was not possible; however, at 90
days (Tg vs NTg) and between 30 and 90 day Tg mice, high
classification performances (AUROC ≥ 0.86) were observed
(Table 1, Supporting Information Figure 3). Examination of
muscle histology is in keeping with these results, with no
pathology evidence at 30 days but marked evidence of
denervation at 90 days (Figure 2). The linear discriminant
(LD) score plots for these comparisons are shown as
histograms, together with the associated loading plots and
tentative peak assignments (Figure 3 and Supporting
Information Figure 4). Average and difference spectra
demonstrated reduced concentrations of phenylalanine (ring
breathing mode, 1000 cm−1), proteins (935, 1044, and 1444
cm−1), and the CO stretching of amide I (1654 cm−1) in
disease states (Supporting Information Figures 2 and 5).
The mdx mouse undergoes an acute onset of disease at
approximately 30 days of age characterized by inflammation
and necrosis, followed by highly effective regeneration25
(Figure 2). We observed a high classification performance at
both 30 and 90 days of age (Table 1, Supporting Information
Figure 2. Intramuscular, in vivo Raman spectra and muscle histology. (a, b) Average spectra are shown for mdx and SOD1G93A, together with the
relevant WT/NTg control for 30 and 90 days of age. Prominent peaks across the different groups are labeled (a and b). (c) Prominent Raman
peaks in baseline subtracted spectra (present also in non-baseline subtracted spectra; Supporting Information Figure 2) and tentative peak
assignments. See Supporting Information Table 1 for peak references. (d) Histological assessment at 30 days in mdx reveals necrotic fibers with
inflammatory cells (arrow) and evidence of early regeneration (small myofibers with central nuclei, arrow heads). (e) The 90 day mdx muscle is
characterized by regenerated myofibers, larger cells with central nuclei (arrow heads). (f) The 30 day SOD1G93A muscle appears normal. The
myofibers have peripheral nuclei and a regular shape. (g, h) The 90 day SOD1G93A muscle displays evidence of denervation in the form of grouped
atrophy (g, double arrow), small angular fibers (g, chevrons), and hypertrophic fibers (h, arrows) and centrally placed nuclei (g, h, arrowhead). (i)
Normal myofibers from a 90 day WT mouse. Magnification for all images = x40, all scale bars = 100 μm. WT = wild type, NTg = nontransgenic.








30 day SOD1G93A/ vs WT
90 day SOD1G93A/ WT 82.5 (±2.0) 78.0 (±3.1) 0.86 (±0.01)
30 day/90 day SOD1G93A 85.5 (±3.8) 86.6 (±2.5) 0.92 (±0.01)
30 day female mdx/ WT 71.3 (±3.1) 65.7 (±2.6) 0.76 (±0.02)
90 day female mdx/ WT 91.6 (±2.2) 76.4 (±3.0) 0.91 (±0.01)
30 day/90 day mdx
(female)
95.6 (±1.8) 71.6 (±3.4) 0.92 (±0.01)
30 day female mdx/
SOD1G93A
89.9 (±1.8) 97.1 (±2.0) 0.97 (±0.01)
90 day female mdx/
SOD1G93A
93.5 (±2.6) 73.3 (±1.7) 0.89 (± 0.02)
aThe different comparisons are shown along with the classification
performance parameters from PCA-LDA. In the 30 day SOD1 vs WT
analysis, there were no significant PCs identified; thus, no model was
generated.
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Figure 3). Comparison of the mdx and SOD1G93A models at
both 30 and 90 days of age demonstrated accurate
identification (AUROC > 0.89) of each disease model
(Table 1).
Examination of the LD loadings for the different analyses
revealed a key spectral fingerprint for muscle health across
both mouse models, comprising similar peaks to those
identified in the difference spectra (Figure 3, Supporting
Information Figures 2 and 4). Tentative assignments are given
in Figure 3. When comparing SOD1G93A and mdx with each
other at 30 days, a similar picture emerges, with key muscle
health peaks attributed to the presymptomatic SOD1G93A
muscle (Supporting Information Figures 2 and 6). At 90
days, when muscle pathology in both models is established,
mdx mice manifest greater losses in protein-related peaks, and
a more complex picture emerges in the multivariate analysis,
with shifts in proteins and lipids across both groups seen
(Supporting Information Figure 6). Lastly, four group models,
comprising 30- and 90-day-old disease-only mice (i.e.,
SOD1G93A and mdx mice), also demonstrated a high
classification performance (Supporting Information Figures 7
and 8).
If in vivo Raman spectroscopy of muscle is to be used in
studies with models such as SOD1G93A and mdx, then it is
important that motor function is not compromised by the
procedure. Motor function testing utilizing the rotarod
demonstrated no significant change in performance at 1 day
after either a Raman or a sham procedure, for any of the
disease groups tested (Figure 4; Supporting Information Figure
9). In the subset of mice undergoing a further recording at 2
weeks postprocedure, no change in performance was seen in
mdx (Figure 4). A significant decline in performance was seen
for the 90 day SOD1G93A group (Figure 4c). Our previous
work has demonstrated a prominent decline in disease-related
motor performance between 90 and 114 days,7 and so we also
tested a cohort of mice that did not undergo either the Raman
or sham procedure (Figure 4d). No significant difference in
rotarod performance was seen across Raman, sham, and no
Figure 3. Linear discriminant function histograms and loadings plots. (a) Linear discriminant function (LDF) histogram and associated loadings
plot for the comparison between 90 day SOD1G93A and NTg mice. (b) Tentative peak assignments for the 90 day SOD1G93A vs NTg comparison.
(c) LDF histogram and associated loadings plot for the comparison between 30-day mdx and WT mice. (d) LDF histogram and associated loadings
plot for the comparison between 90 day mdx and WT mice. (e) Tentative peak assignments for the mdx vs WT comparisons. Peak references can
be found in Supporting Information Table 1. Wn = wavenumber.
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procedure groups, indicating a disease-related performance
decline. In addition, a comprehensive assessment of gait using
the catwalk gait analysis system did not demonstrate any
systematic effect (Supporting Information Figure 10).
Assessment for subclinical muscle injury was performed
using high-resolution MRI. WT mice were used to avoid
pathological changes relating to disease complicating image
interpretation. In mice undergoing MRI at 6 h post-Raman (n
= 3), we observed subtle T2 hyperintensities in the
gastrocnemius muscles around the site of needle placement
(Figure 5). In one mouse, similar changes were apparent at 2
days; no changes were seen in any mice at 2 weeks
postprocedure. No signal changes were apparent in mice
undergoing the sham procedure (Figure 5). These results may
suggest that laser exposure induces a degree of thermal injury,
Figure 4. Post-in vivo Raman spectroscopy motor performance. Rotarod performance for 30 day SOD1G93A mice for both Raman (a) and sham (b)
experiments. At 90 days of age, a significant decline in performance was seen two weeks postprocedure (c). However, there was no difference in
rotarod performance at this final age (104 days) between mice undergoing Raman, sham, and no procedure (d), suggesting a disease-related
decline. No change in rotarod performance was seen at either 30 days (e, f) or 90 days (g, h) in the mdx mice. ** = P < 0.01. d = day; wks = weeks.
Figure 5. 7T MRI evaluation of muscle that has undergone in vivo Raman spectroscopy. (a) Axial MRI (ex vivo) from NTg (healthy) mice. Muscles
were studied at three different time points post-Raman measurement. Each panel represents a different mouse. The yellow arrows denote high T2
signal which may be due to postprocedure edema. (b) Axial MRI (ex vivo) from two time points following a sham procedure. Each panel represents
a different mouse.
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although we were only able to scan a small number of mice in
both the Raman and sham groups.
Finally, to explore the translation potential of fiber optic
Raman spectroscopy we undertook ex vivo recordings from
human muscle samples obtained from patients with ALS (n =
3) and DMD (n = 3) (Figure 6). The ex vivo human spectra
appeared similar to the in vivo mouse spectra. The limited
availability of muscle tissue from children with muscle diseases
means that a robust assessment of the classification perform-
ance between ALS and DMD human samples is not possible
with these data. However, differences in the spectra were
apparent, even without chemometric analysis (see also
Supporting Information Figure 11).
Our results demonstrate that in vivo fiber optic Raman
spectroscopy can identify muscle pathology in murine models
of human neuromuscular disease. The simplicity of Raman
spectroscopy offers potential as a translational biomarker in
both preclinical and clinical studies.
In analyses based on spectral differences (both simple
subtraction and multivariate statistics), a key fingerprint for
muscle health emerged. Peaks associated with phenylalanine
(1000 cm−1) and α-helical protein content (e.g., 935, 1300-5,
1654 cm−1) were seen to reduce in disease states, including
with progression of the disease. These protein changes may
represent the relative loss of the long α-helical structures
within muscle proteins,26 as well as membrane phospholipids
and proline, which act to enhance protein synthesis in
muscle.27 When comparing fly models of different human
muscle diseases, Gautam et al. also observed a reduction in α-
helix content in the disease models.22 Of note, transcriptome
studies in SOD1 mouse models of both ALS and DMD
indicate upregulation of genes associated with protein
degradation.28−30 As α-helices are the most abundant
structures in proteins, our results would be in keeping protein
breakdown. In addition, oxidative stress, known to occur in the
muscles of both mouse models,31,32 has been shown to cause
similar structural changes in different tissues/cells.33−35
Our methodology did not appear to result in any functional
impairment using two standard methods of monitoring skeletal
muscle function (rotarod and catwalk). In the catwalk analyses,
a small number of postprocedure changes were observed, but
these were not consistent. While catwalk is commonly used in
studies concerning muscle injury and neuromuscular function,
there are concerns regarding the reliability of the tests.36 Some
authors suggest only using a certain set of parameters, none of
which manifested changes in our analyses. Similarly, we did not
observe changes in gait parameters documented by others after
muscle injury.37,38 Overall, the lack of effect on motor function
suggests that our approach can be incorporated into preclinical
studies.
MRI studies demonstrated a transient change in T2 muscle
signal postprocedure, which likely reflects edema cause by a
resolving inflammatory response. In murine models of muscle
injury and human subjects after intramuscular injection, similar
time-limited changes in T2 signal intensity have been
reported.39−41 We did attempt to undertake in vivo imaging
with a view to complete serial scans in the same mouse, which
would have allowed more mice to be imaged; however, long
scan times failed to produce the desired resolution (data not
shown).
Our approach has several strengths that make it appealing
for use in future preclinical studies. The procedure can be
performed under a standard anesthetic protocol and is quick to
perform. The collection of Raman spectra took no more than 3
min; this contrasts to recording times of around 1 h required
for in vivo MRI.8 Unlike new in vivo confocal imaging
approaches,42 our Raman spectroscopy method requires no
tissue preparation or prelabeling.
In the present study, we made several compromises in the in
vivo recording protocol to reduce the potential for tissue
damage. Probe diameter was limited to 0.5 mm to reduce the
trauma of the insertion. A larger probe with a higher etendue
for light collection may facilitate a better signal-to-noise ratio,
as might longer acquisition times and/or increased laser power.
However, the latter two would increase thermal energy
exposure and possibly exacerbate any tissue injury. In this
regard it is encouraging that in vivo human studies across a
range of tissues and using a variety of laser powers/probe sizes
have not reported any significant tissue damage.43,19,44 The
fiber optic probe, operating at 60 mW laser power, has a
maximum power density of 7.6 Wmm−2 at the distal tip, which
is orders of magnitude below that typically used in conven-
tional microscope-based systems. Furthermore, we only
observed a transient tissue damage known to occur with
procedures involving needle penetration of muscle.40,45 The
relative size of the needle to the muscle being studied is also
much larger in mice than would be the case in most human
muscles. Thus, in vivo human recordings should be technically
and practically feasible, although as with any new application of
Figure 6. Human muscle spectra (ex vivo) and corresponding in vivo mouse model spectra. (a) Average ex vivo muscle spectra from patients with
MND (orange) and in vivo spectra from 90 day-old SOD1G93A mice (blue). (b) Average ex vivo muscle spectra from patients with DMD (orange)
and in vivo spectra from 90 day-old mdx mice (blue).
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biophotonics, widespread uptake of the technique is likely to
take time to realize.
In summary, our results demonstrate the use of minimally
invasive fiber-optic spontaneous Raman spectroscopy for the in
vivo assessment of muscle in preclinical models of neuro-
muscular diseases. The technique accurately distinguished
between different types and stages of muscle disease. No
impairment of motor function was seen, making it amenable
for incorporation into preclinical drug studies. Analysis of ex
vivo human muscle specimens demonstrated the translational
potential of the technique. Spontaneous Raman spectroscopy
of muscle is a promising biomarker for devastating human
neuromuscular diseases.
■ METHODS
Details on the animal models used, human muscle samples, MRI
methodology, histology, and motor function assessments can be
found in the Supporting Information. Further details on data analysis
can also be found in the Supporting Information.
In Vivo Fiber Optic Raman Spectroscopy. Mice were
anaesthetised using 2% isoflurane and positioned on a heat pad to
maintain body temperature. The hindlimbs were shaved, and the fiber
optic needle probe was inserted into the medial and lateral heads of
both gastrocnemius muscles (Figure 1). The total time under
anesthesia was 4 min.
The novel miniature (0.5 mm) fiber optic Raman probe was
housed inside a standard 21 guage hypodermic needle. The design
was based on that presented by Day and Stone46 and is shown
schematically in Figure 1. A 830 nm semiconductor laser (Innovative
Photonics Solutions) was used to provide a superior signal/noise ratio
due to lower background fluorescence than shorter wavelength
excitation.19,47 In line filters were placed approximately 15 cm from
the probe tip to reduce the effect of Raman and fluorescence
generated in the delivery fibers. These comprised a bandpass filter on
the excitation delivery fiber and a long-pass filter on the collection
fiber (Semrock Inc.). All fibers were low OH, with a 105 μm silica
core of NA 0.22. The probe was optically matched to the
spectrometer (Raman Explorer Spectrograph, Headwall Photonics,
Inc. and iDus 420BR-DD CCD camera, Andor Technology, Ltd.) for
optimum efficiency. A robust Raman signal of interest was recorded
through a 40 s exposure consisting of 10 × 4 s epochs which were
averaged. Beam divergence, with a 60 mW laser power at the probe tip
and a near-infrared laser, reduces the potential for tissue damage
through a lower energy density.14 Spectra from PTFE were acquired
for wavenumber calibration. Following PTFE offset correction, an air
background signal was recorded to check consistency across
measurements. Spectra were acquired over a 2 year period with
multiple groups of mice (i.e., both SOD1G93A/mdx and different ages)
tested at each sitting to avoid any unknown factors confounding the
results of a single group. All comparisons between disease and WT/
NTg used n = 16 mice in each group. For assessment of muscle injury,
a sham procedure was also used in which mice underwent the same
procedure as above, with the exception that the laser was not switched
on.
Data Analysis. Over 6000 spectra were available for analysis,
which was done using MATLAB (MATLAB R2019b The Math-
Works, Inc., Natick, MA). Raw spectra were interpolated between 900
and 1800 cm−1, normalized using standard normal variate normal-
ization (SNV)48 and mean-centered. Spectra were windowed between
900 and 1800 cm−1, as outside this region, the spectra were
dominated by peaks and background related to the silica in the optical
fibers (before 900 cm−1) or consisted of uninformative noise (after
1800 cm−1). Human tissue spectra (but not mouse spectra) were
smoothed using a fifth order Savitzky−Golay filter49 (window width =
15 data points).
Principal component analysis-fed linear discriminant analysis
(PCA-LDA), principal component analysis-fed quadratic discriminant
analysis (PCA-QDA), and partial least-squares discriminant analysis
(PLS-DA) classification models were generated for all the data sets.
The first 10 principal components (PCs) were interrogated for
significant between group differences using student’s t test or analysis
of variance (ANOVA), followed by false discovery rate (fdr)
correction (Q = 0.05). Those PCs demonstrating significant
differences between the groups under assessment were used as inputs
to LDA. Linear discriminant functions (LDFs) using PCs identified as
statistically significant were plotted in order to illustrate the important
peaks for spectral classification. For PLS-DA (Supporting Informa-
tion), selection of the optimal number of latent variables was done by
increasing their number until prediction accuracy no longer increased.
The classification performance of the different models was validated
using repeated leave-some-mice-out-cross-validation (RLSMOCV).
The analysis was repeated 100 times using randomly selected
combinations of left-out-mice. Area under the receiver operating
characteristic curve (AUROC) was calculated. These curves plot the
true positive rate (sensitivity) against the false positive rate (1-
sensitivity) and illustrate the ability of a classifier to separate classes.
As performance across the different classification algorithms was
similar, PCA-LDA results are shown in the main text using linear
discriminant loadings plots.14 These combine the information from
relevant PCs, thus providing a more comprehensive exploration of the
spectral features underlying class differentiation than single PC or
latent variable loadings plots.
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